<DOC>
	<DOCNO>NCT02312570</DOCNO>
	<brief_summary>To assess efficacy Eclipse PRP™ Wound Biomatrix compare performance usual customary practice treatment chronic non-healing pressure ulcer ( PU ) .</brief_summary>
	<brief_title>Clinical Trial ECLIPSE PRP™ Wound Biomatrix Chronic Non-Healing Pressure Ulcers</brief_title>
	<detailed_description>This prospective , randomize , single-blind , control , multi-center study subject undergo PU treatment . Qualified subject randomize ( 1:1 ) ; test group ( Eclipse PRP™ Wound Biomatrix ) control group ( usual customary practice ) . The study consist 3 period : screening period , active treatment period , follow-up period ( heal ) . Approximately 250 subject enrol . Subjects ≥18 year age PU ( great 4 week duration ) . Each subject enrol active treatment period 12 week , closure wind confirmatory visit 2 week wound closure , whether closure occur 12 week earlier .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Pressure Ulcer</mesh_term>
	<criteria>Medicare/Medicaid eligible Ulcer pressure/shear etiology The index ulcer great 4 week duration . Three few ulcer separate &gt; 3.0 cm distance The large nonhealing wound , multiple wound present , single wound treat ( Index Ulcer ) locate heel , ischium , sacrum , trochanter Postdebridement , ulcer size must 2 cm2 200 cm2 Demonstrated adequate offload regimen Able willing attend schedule followup visit study related exam Able willing provide voluntary write informed consent Stage I pressure ulcers Ulcers unstageable deep tissue morphology yet become open wound Ulcer PU pathophysiology ( e.g. , pure diabetic , vasculitic , radiation , rheumatoid , collagen vascular disease , venous , arterial etiology ) Greater 30 % reduction wound size first two week observation treatment investigator Gross clinical infection study ulcer site include cellulitis osteomyelitis . Known allergy tor sensitivity Eclipse PRP kit component ( calcium chloride , calcium gluconate acid citrate dextrose solution A ( ACDA ) ) Serum albumin le 2.5 g/dL , Plasma Platelet count le 100 x 109/L , Hemoglobin le 10.5 g/dL Known renal failure determine Creatinine &gt; 2.5 mg/dl Malignancy near ulcer site Rheumatoid arthritis ( collagen vascular disease ) , vasculitis , sickle cell disease , HIV Severe liver disease . Presence additional abnormal lab value obtain within 7 day prior Day 0 visit determine clinically significant investigator include : WBC &gt; 13,000/cm3 &lt; 5 , 000 cm3 , electrolytes outside host institution 's range normal Radiation therapy , chemotherapy , immunosuppressive therapy chronic steroid use within 30 day enrollment Received another investigational device drug within 30 day enrollment Received allograft , autograft xenograft within 30 day enrollment Subject inadequate venous access repeat blood draw require Eclipse RPR administration Subject require anticipated require intervention direct improvement arterial perfusion affect area Ulcer expect treated advanced therapeutic ( e.g. , HBOT ) Presence another wound concurrently treat might interfere treatment index wind Subjects cognitively impair healthcare proxy Life expectancy &lt; 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>non-healing wound</keyword>
	<keyword>pressure ulcer</keyword>
	<keyword>platelet rich plasma</keyword>
</DOC>